J-M Ye1, N Dzamko1, M E Cleasby1, B D Hegarty1, S M Furler1, G J Cooney1, E W Kraegen2. 1. Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia. 2. Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia. e.kraegen@garvan.org.au.
Abstract
AIMS/HYPOTHESIS: Thiazolidinediones can enhance clearance of whole-body non-esterified fatty acids and protect against the insulin resistance that develops during an acute lipid load. The present study used [(3)H]-R-bromopalmitate to compare the effects of the thiazolidinedione, rosiglitazone, and the biguanide, metformin, on insulin action and the tissue-specific fate of non-esterified fatty acids in rats during lipid infusion. METHODS: Normal rats were treated with rosiglitazone or metformin for 7 days. Triglyceride/heparin (to elevate non-esterified fatty acids) or glycerol (control) were then infused for 5 h, with a hyperinsulinaemic clamp being performed between the 3rd and 5th hours. RESULTS: Rosiglitazone and metformin prevented fatty-acid-induced insulin resistance (reduced clamp glucose infusion rate). Both drugs improved insulin-mediated suppression of hepatic glucose output but only rosiglitazone enhanced systemic non-esterified fatty acid clearance (plateau plasma non-esterified fatty acids reduced by 40%). Despite this decrease in plateau plasma non-esterified fatty acids, rosiglitazone increased fatty acid uptake (two-fold) into adipose tissue and reduced fatty acid uptake into liver (by 40%) and muscle (by 30%), as well as reducing liver long-chain fatty acyl CoA accumulation (by 30%). Both rosiglitazone and metformin increased liver AMP-activated protein kinase activity, a possible mediator of the protective effects on insulin action, but in contrast to rosiglitazone, metformin had no significant effect on non-esterified fatty acid kinetics or relative tissue fatty acid uptake. CONCLUSIONS/ INTERPRETATION: These results directly demonstrate the "lipid steal" mechanism, by which thiazolidinediones help prevent fatty-acid-induced insulin resistance. The contrasting mechanisms of action of rosiglitazone and metformin could be beneficial when both drugs are used in combination to treat insulin resistance.
AIMS/HYPOTHESIS: Thiazolidinediones can enhance clearance of whole-body non-esterifiedfatty acids and protect against the insulin resistance that develops during an acute lipid load. The present study used [(3)H]-R-bromopalmitate to compare the effects of the thiazolidinedione, rosiglitazone, and the biguanide, metformin, on insulin action and the tissue-specific fate of non-esterifiedfatty acids in rats during lipid infusion. METHODS: Normal rats were treated with rosiglitazone or metformin for 7 days. Triglyceride/heparin (to elevate non-esterifiedfatty acids) or glycerol (control) were then infused for 5 h, with a hyperinsulinaemic clamp being performed between the 3rd and 5th hours. RESULTS:Rosiglitazone and metformin prevented fatty-acid-induced insulin resistance (reduced clamp glucose infusion rate). Both drugs improved insulin-mediated suppression of hepatic glucose output but only rosiglitazone enhanced systemic non-esterifiedfatty acid clearance (plateau plasma non-esterifiedfatty acids reduced by 40%). Despite this decrease in plateau plasma non-esterifiedfatty acids, rosiglitazone increased fatty acid uptake (two-fold) into adipose tissue and reduced fatty acid uptake into liver (by 40%) and muscle (by 30%), as well as reducing liver long-chain fatty acyl CoA accumulation (by 30%). Both rosiglitazone and metformin increased liver AMP-activated protein kinase activity, a possible mediator of the protective effects on insulin action, but in contrast to rosiglitazone, metformin had no significant effect on non-esterifiedfatty acid kinetics or relative tissue fatty acid uptake. CONCLUSIONS/ INTERPRETATION: These results directly demonstrate the "lipid steal" mechanism, by which thiazolidinediones help prevent fatty-acid-induced insulin resistance. The contrasting mechanisms of action of rosiglitazone and metformin could be beneficial when both drugs are used in combination to treat insulin resistance.
Authors: B E Kemp; D Stapleton; D J Campbell; Z-P Chen; S Murthy; M Walter; A Gupta; J J Adams; F Katsis; B van Denderen; I G Jennings; T Iseli; B J Michell; L A Witters Journal: Biochem Soc Trans Date: 2003-02 Impact factor: 5.407
Authors: A M Lefebvre; J Peinado-Onsurbe; I Leitersdorf; M R Briggs; J R Paterniti; J C Fruchart; C Fievet; J Auwerx; B Staels Journal: Arterioscler Thromb Vasc Biol Date: 1997-09 Impact factor: 8.311
Authors: Jonathan S Fisher; Jiaping Gao; Dong-Ho Han; John O Holloszy; Lorraine A Nolte Journal: Am J Physiol Endocrinol Metab Date: 2002-01 Impact factor: 4.310
Authors: Ji-Ming Ye; Miguel A Iglesias; David G Watson; Bronwyn Ellis; Leonie Wood; Per Bo Jensen; Rikke Veggerby Sørensen; Philip Just Larsen; Gregory J Cooney; Karsten Wassermann; Edward W Kraegen Journal: Am J Physiol Endocrinol Metab Date: 2003-03 Impact factor: 4.310
Authors: Andrea L Hevener; Weimin He; Yaacov Barak; Jamie Le; Gautam Bandyopadhyay; Peter Olson; Jason Wilkes; Ronald M Evans; Jerrold Olefsky Journal: Nat Med Date: 2003-11-16 Impact factor: 53.440
Authors: Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda Journal: FASEB J Date: 2010-05-25 Impact factor: 5.191
Authors: Jeff Ishibashi; Zeynep Firtina; Sona Rajakumari; Kathleen H Wood; Heather M Conroe; David J Steger; Patrick Seale Journal: Mol Cell Biol Date: 2012-04-02 Impact factor: 4.272
Authors: A L Carey; E Wolsk Petersen; C R Bruce; R J Southgate; H Pilegaard; J A Hawley; B K Pedersen; M A Febbraio Journal: Diabetologia Date: 2006-03-15 Impact factor: 10.122
Authors: Julien Lamontagne; Emilie Pepin; Marie-Line Peyot; Erik Joly; Neil B Ruderman; Vincent Poitout; S R Murthy Madiraju; Christopher J Nolan; Marc Prentki Journal: Endocrinology Date: 2009-04-30 Impact factor: 4.736
Authors: Carley R Benton; Graham P Holloway; S E Campbell; Yuko Yoshida; Narendra N Tandon; Jan F C Glatz; Joost J J F P Luiken; Lawrence L Spriet; Arend Bonen Journal: J Physiol Date: 2008-01-31 Impact factor: 5.182